Literature DB >> 6168361

Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction.

L H Einhorn, S D Williams, I Mandelbaum, J P Donohue.   

Abstract

Platinum combination chemotherapy will regularly produce a 70% complete response rate in testicular cancer. Many patients failing to achieve complete remission can still be rendered disease-free with surgical resection of residual localized disease. Twenty-one patients underwent resection for residual pulmonary lesions and 41 underwent lymphadenectomy for persistent retroperitoneal disease. There were no characteristic radiographic findings for fibrous tissue versus mature teratoma versus carcinoma. Although elevated HCG or AFP levels indicated the presence of carcinoma, negative HCG and AFP did not rule out such a diagnosis as 12 of 22 resected carcinoma patients were seronegative. Of 35 patients, 31 (89%) with fibrous tissue or mature teratomas and all four patients with immature teratomas have been continuously free of disease with a minimal postoperative follow-up time of six months. However, only two of 22 patients with resected carcinomas have been continuously disease-free. Post-operative chemotherapy for mature teratoma or fibrous tissue is probably not necessary. However, we feel that further aggressive chemotherapy is needed in the resected carcinoma patient with at least two courses of platinum combination chemotherapy. Surgical resection of residual disease following chemotherapy-induced cytoreduction with platinum combination chemotherapy may be therapeutic in some cases and helps to define the optimal subsequent treatment strategy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6168361     DOI: 10.1002/1097-0142(19810815)48:4<904::aid-cncr2820480407>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Testicular germ cell tumours--a model for a new approach to treatment of adult solid tumours.

Authors:  R T Oliver
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

Review 2.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

3.  Findings in lymph nodes of patients with germ cell tumours after chemotherapy and their relation to prognosis.

Authors:  R J Zuk; B J Jenkins; J E Martin; R T Oliver; S I Baithun
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 4.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

5.  Germ cell testicular tumours with lung metastases: chemotherapy and surgical treatment.

Authors:  S Cărsky; D Ondrus; M Schnorrer; M Májek
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

6.  Unusual neoplasms detected in testicular cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy.

Authors:  J S Little; R S Foster; T M Ulbright; J P Donohue
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 7.  Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis.

Authors:  J P Donohue; E P Fox; S D Williams; P J Loehrer; T M Ulbright; L H Einhorn; T D Weathers
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

Review 8.  Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer.

Authors:  Stephen D W Beck; Richard S Foster
Journal:  World J Urol       Date:  2006-03-08       Impact factor: 4.226

Review 9.  The detection and evaluation of human tumor metastases.

Authors:  D J Laurence; A M Neville
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  The changing role of surgery in metastatic non-seminomatous germ cell tumour.

Authors:  J Cassidy; C R Lewis; S B Kaye; D Kirk
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.